株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

抗高血圧薬市場(〜2017年):ブロックバスター薬(Diovan、Micardis、Avapro、Atacandなど)の特許失効が目減りを加速

Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion

発行 GBI Research 商品コード 235092
出版日 ページ情報 英文 119 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
抗高血圧薬市場(〜2017年):ブロックバスター薬(Diovan、Micardis、Avapro、Atacandなど)の特許失効が目減りを加速 Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion
出版日: 2012年03月23日 ページ情報: 英文 119 Pages
概要

当レポートでは、世界の抗高血圧薬(降圧剤)市場について調査分析し、高血圧症と肺動脈高血圧症(PAH)について検証し、ジェネリック薬の市場シェア、降圧剤の使用パターン、地域分析、パイプライン分析、競合分析などを提供し、2017年までの市場予測や主要企業プロファイルも含めて、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 市場概要

  • イントロダクション
  • 世界の抗高血圧薬市場の収益予測
  • 抗高血圧薬市場の促進要因
  • 抗高血圧薬市場の抑制要因
  • 世界の抗高血圧薬市場におけるジェネリック薬のシェア

第4章 治療情勢

  • 高血圧症
  • 肺動脈高血圧症(PAH)市場

第5章 地域情勢

  • 地域区分
  • 米国
  • 欧州の主要5ヶ国
  • 日本

第6章 パイプライン分析

  • イントロダクション
  • 抗高血圧薬市場における主な後期開発薬のプロファイル

第7章 競合情勢

  • 市場シェア分析
  • 競合企業プロファイル
    • Novartis
    • Merck
    • 第一三共
    • Sanofi
    • AstraZeneca
    • United Therapeutics
    • Actelion
    • Pfizer

第8章 戦略的統合

  • 概要
  • タイプ別取引
  • 研究開発ライセンス契約

第9章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Summary

GBI Research, the leading business intelligence provider, has released its latest research "Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion", which provides insights into the anti-hypertensives therapeutics market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of hypertension and pulmonary arterial hypertension. It also provides the share of generics in global anti-hypertensives and in each indication market. The report examines the global anti-hypertensives usage patterns. It includes the geographical distribution of hypertension and PAH disease markets across the US, the top five countries of Europe and in Japan. The report also includes insights into the anti-hypertensives Research and Development (R&D) product pipeline and explores the competitive landscape, including major players in the anti-hypertensives market. Finally, the report includes analysis on Mergers and Acquisitions (M&A) and licensing agreements that took place in the anti-hypertensives market.

GBI Research's analysis shows that the overall global anti-hypertensives market for two indications, hypertension and pulmonary arterial hypertension, was valued at $29.9 billion in 2010. It grew from $19.1 billion in 2002 at a CAGR of 5.8%. The market is expected to witness a fluctuation due to patent expiries followed by generic erosion and the possible launch of novel molecules. The market is expected to witness comparatively slow growth with a CAGR of 1.2% between 2010 and 2017, to reach $32.6 billion in 2017. A steady increase in the hypertension and PAH prevalence population and the use of fixed dose combination drugs will drive the growth of the anti-hypertensives market in the future. The market for hypertension market is expected to slow down due to patent expiries of major blockbuster drugs. Recent and upcoming patent expiries of drugs are the only barrier to the global anti-hypertensives market. However, the expected launch of novel molecules with disease modifying characteristics and better safety and efficacy will drive the market in the forecast period.

Scope

  • The report analyzes treatment usage patterns, market characterization, pipeline analysis, competitive landscape and key M&A trends in the global anti-hypertensives market for two indications, hypertension and pulmonary arterial hypertension.
  • Data and analysis on the anti-hypertensives market in the leading geographies of the world - the US, the UK, Germany, France, Italy, Spain and Japan.
  • Annualized market data for the anti-hypertensives market from 2002 to 2010, with forecasts to 2017.
  • Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
  • Share of the generics in global anti-hypertensives market and for the market of each indication that is covered in the report.
  • Key drivers and restraints that have had a significant impact on the market.
  • The competitive landscape of the global market including top companies benchmarking. The key companies studied in this report are Novartis, Daiichi Sankyo, Merck, Pfizer, AstraZeneca, Sanofi, Takeda and Boehringer Ingelheim.
  • Key M&A activities and licensing agreements that took place between 2009 and 2011 in the anti-hypertensives market.

Reasons to buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to -

  • Align your product portfolio to the markets with high growth potential.
  • Build effective strategies to launch their pipeline products by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of top competitors.
  • Create a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
  • Develop market entry and market expansion strategies by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

Executive Summary

GBI Research, the leading business intelligence provider, has released its latest research "Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion" which provides insights into the anti-hypertensives therapeutics market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of hypertension and pulmonary arterial hypertension. It also provides the share of generics in global anti-hypertensives and in each indication market. The report examines the global anti-hypertensives usage patterns. It includes the geographical distribution of hypertension and PAH disease markets across the US, the top five countries of Europe and in Japan. The report also includes insights into the anti-hypertensives Research and Development (R&D) product pipeline and explores the competitive landscape, including major players in the anti-hypertensives market. Finally, the report includes analysis on Mergers and Acquisitions (M&A) and licensing agreements that took place in the anti-hypertensives market. GBI Research's analysis shows that the overall global anti-hypertensives market for two indications, hypertension and pulmonary arterial hypertension, was valued at $29.9 billion in 2010. It grew from $19.1 billion in 2002 at a CAGR of 5.8%. The market is expected to witness a fluctuation due to patent expiries followed by generic erosion and the possible launch of novel molecules. The market is expected to witness comparatively slow growth with a CAGR of 1.2% between 2010 and 2017, to reach $32.6 billion in 2017. A steady increase in the hypertension and PAH prevalence population and the use of fixed dose combination drugs will drive the growth of the anti-hypertensives market in the future. The market for hypertension market is expected to slow down due to patent expiries of major blockbuster drugs. Recent and upcoming patent expiries of drugs are the only barrier to the global anti-hypertensives market. However, the expected launch of novel molecules with disease modifying characteristics and better safety and efficacy will drive the market in the forecast period.

The Global Anti-Hypertensives Market is Set to Show Flat Growth in the Near Future

The global anti-hypertensives market was estimated to be worth $29.9 billion in 2010, representing a Compound Annual Growth Rate (CAGR) of 5.8% between 2002 and 2010. The market is forecast to reach $33 billion by 2017 at a CAGR of 1.2%. The primary reason for the slow down in the market growth is the patent expiries of major blockbusters in the forecast period. Drugs that are set to lose patent include Novartis' Diovan (2012), Sanofi's Avapro (2012), Novartis's Exforge (2012), Takeda/AstraZeneca's Blopress/Atacand (2012), Pfizer's Revatio (2012), Boehringer's Micardis (2014), United Therapeutics Remodulin (2014), Actelion's Tracleer (2015) and Daiichi Sankyo's Benicar (2016). These drugs together accounted for more than $20.6 billion in revenues in 2010.

However, the market is expected to rise slightly after 2015 due to increased usage of fixed dose-combinations and the increase in prescription population on generics. The new fixed dose combinations which entered the antihypertensives market recently are Exforge HCT, Tektuna HCT, Tekamlo, Valturna, Tribenzor, Twynsta, Edarbi and Amturnide.

The current anti-hypertensives pipeline offers some promising novel products indicated for the treatment of hypertension and PAH such as SPP635, Actos, LCZ696, QT1571, ACT-293987, PS-433540, Macitentan and Riociguat. However, the revenues that will be generated from these products are not expected to completely make up for the revenue losses due to patent expiries.

Top Six Companies Contribute About 76% of the Market

The current global anti-hypertensives market is dominated by the top six players with 76% of the market share. Novartis is the current market leader with 28% of the market share due to its blockbuster drug Diovan which made sales of six billion US dollars in 2010. Novartis' other major products in the anti-hypertensives market are Exforge, Tekturna/Rasilez, Lotrel and Lescol. Daiichi Sankyo is the second largest player with 14% of the market share. Benicar is the top selling drug in Daiichi Sankyo's anti-hypertensives drug portfolio. AstraZeneca and Sanofi occupy third position with 10% of each due to their top selling drugs Atacand and Avapro respectively. Pfizer's Norvasc and Merck's Cozaar lost their patents in 2007 and 2010 respectively which landed up Pfizer and Merck with 7% of market share each. However, Pfizer's Revatio is one of the top selling drug in the PAH market. Boehringer Ingelheim also has a significant share in the market with its drug Micardis. Actelion is the market leader in PAH market with its blockbuster drugs Tracleer and Ventavis and occupies 6% of the market share.

However, the market shares of the total players are expected to witness changes in the future due to upcoming patent expiries. Novartis' Diovan, Exforge and Tekturna/Rasilez are set to expire in 2012. Daiichi Sankyo is expected to lead the market with its Benicar whose patent is valid until 2014.

Novartis to Lead the Anti-Hypertensives Market

The anti-hypertensives drug category was the largest selling subcategory of the cardiovascular market in 2010. Novartis is the market leader in the anti-hypertensives market, with a large number of marketed products. Key products of Novartis include Diovan, Diovan HCT, Exforge, Tekturna/Rasilez, Lotrel and Lescol. Boehringer Ingelheim's Micardis, Daiichi Sankyo's Benicar, Takeda's Blopress and AstraZeneca's Atacand are other top selling drugs. Pfizer's Norvasc was the market leader until 2007. Norvasc went off-patent in 2007, giving a major share of the market to Novartis' Diovan and Merck's Cozaar. The first ARB to lose patent was Cozaar in April 2010. Novartis' Diovan is set to lose patent in 2012. Novartis launched its other fixed dose combination drugs in 2010 such as Exforge HCT, Tektuna HCT, Tekamlo, Valturna and Amturnide. These drugs together with the earlier drugs expect to keep Novartis the anti-hypertensives market leader. Sanofi's Avapro is also one of the leading drugs in the anti-hypertensives market, registering high sales over the years. It is also expected to go off-patent in 2012. Actelion's Tracleer, the most prescribed PAH therapy in the world, is set to expire in 2015. Thus Novartis will lead the anti-hypertensives market with a large number of blockbuster drugs and fixed dose combination drugs.

Table of Contents

1 Table of Contents 3

  • 1.1 List of Tables 5
  • 1.2 List of Figures 7

2 Global Anti-Hypertensives Market - Introduction 9

  • 2.1 GBI Research Report Guidance 10

3 Global Anti-Hypertensives Market - Market Overview 11

  • 3.1 Introduction 11
  • 3.2 Revenue Forecasts for the Global Anti-Hypertensives Market 12
    • 3.2.1 Revenue 12
    • 3.2.2 Annual Cost of Therapy 13
    • 3.2.3 Treatment Usage Patterns 14
  • 3.3 Anti-Hypertensives Market Drivers 19
    • 3.3.1 Uptake of Fixed Dose Combination Therapies due to Better Efficacy in Hypertension and Pulmonary Arterial Hypertension 19
  • 3.4 Anti-Hypertensives Market Restraints 19
    • 3.4.1 Low Compliance in Hypertensive Patients 19
    • 3.4.2 Patent Expiries of Major Blockbusters Including Diovan, Avapro, Blopress/Atacand, Cozaar/Hyzaar and Tracleer, Pose a Threat to Market Revenues 19
    • 3.4.3 Low Treatment Seeking Behavior and Diagnosis in Pulmonary Arterial Hypertension 20
  • 3.5 Generics Share in the Global Anti-Hypertensives Market 21

4 Global Anti-Hypertensives Market: Therapeutic Landscape 22

  • 4.1 Hypertension 22
    • 4.1.1 Introduction 22
    • 4.1.2 Treatment Flow Algorithm for Hypertension 23
    • 4.1.3 Revenue 23
    • 4.1.4 Annual Cost of Therapy 25
    • 4.1.5 Treatment Usage Patterns 27
    • 4.1.6 Market Segmentation by Geography 32
  • 4.2 Pulmonary Arterial Hypertension (PAH) Market 35
    • 4.2.1 Introduction 35
    • 4.2.2 Treatment Flow Algorithm for Pulmonary Arterial Hypertension 37
    • 4.2.3 Revenue 38
    • 4.2.4 Annual Cost of Therapy 39
    • 4.2.5 Treatment Usage Patterns 40
    • 4.2.6 Market Segmentation by Geography 45

5 Global Anti-Hypertensives Market - Geographical Landscape 48

  • 5.1 Geographical Break-up 48
  • 5.2 The US 51
    • 5.2.1 Revenue 51
    • 5.2.2 Annual Cost of Therapy 52
    • 5.2.3 Treatment Usage Patterns 53
  • 5.3 Top Five Countries in Europe 58
    • 5.3.1 Revenue 58
    • 5.3.2 Revenue by Country 59
    • 5.3.3 Annual Cost of Therapy 60
    • 5.3.4 Treatment Usage Patterns 62
  • 5.4 Japan 67
    • 5.4.1 Revenue 67
    • 5.4.2 Annual Cost of Therapy 68
    • 5.4.3 Treatment Usage Patterns 69

6 Global Anti-Hypertensives Market - Pipeline Analysis 74

  • 6.1 Introduction 74
    • 6.1.1 Research and Development Pipeline - Hypertension 76
    • 6.1.2 Research and Development Pipeline - Pulmonary Arterial Hypertension 80
  • 6.2 Profiles of Key Late-Stage Drugs in the Anti-Hypertension Market 83
    • 6.2.1 SPP635 83
    • 6.2.2 Pioglitazone 83
    • 6.2.3 LCZ696 84
    • 6.2.4 QT1571 (Imatinib) 85
    • 6.2.5 Selexipag (NS-304, ACT-293987) 86
    • 6.2.6 PS-433540 (DARA) 86
    • 6.2.7 Macitentan (ACT-064992, Actelion 1) 87
    • 6.2.8 Riociguat (BAY63-2521) 88

7 Global Anti-Hypertensives Market - Competitive Landscape 90

  • 7.1 Market Share Analysis 90
  • 7.2 Competitive Profiling 91
    • 7.2.1 Novartis 91
    • 7.2.2 Merck 92
    • 7.2.3 Daiichi Sankyo 93
    • 7.2.4 Sanofi 94
    • 7.2.5 AstraZeneca 95
    • 7.2.6 United Therapeutics 97
    • 7.2.7 Actelion 98
    • 7.2.8 Pfizer 100

8 Global Anti-Hypertensives Market - Strategic Consolidations 102

  • 8.1 Overview 102
  • 8.2 Deals by Type 102
    • 8.2.1 M&A Deals by Indication 103
    • 8.2.2 M&A Deals by Year 103
    • 8.2.3 M&A Deals by Geography 104
    • 8.2.4 Summary of Major M&A Deals 105
  • 8.3 R&D Licensing Agreements 107
    • 8.3.1 Licensing Agreements by Indication 107
    • 8.3.2 Licensing Agreements by Phase 108
    • 8.3.3 Licensing Agreements by Geography 108
    • 8.3.4 Licensing Agreements for Drugs in Phase II and Phase III Stage 109
    • 8.3.5 Licensing Agreements for Approved Drugs 110

9 Global Anti-Hypertensives Market - Appendix 112

  • 9.1 Market Definitions 112
  • 9.2 Abbreviations 112
  • 9.3 Research Methodology 114
    • 9.3.1 Coverage 114
    • 9.3.2 Secondary Research 114
    • 9.3.3 Primary Research 114
    • 9.3.4 Therapeutic Landscape 115
    • 9.3.5 Market Size by Geography 116
    • 9.3.6 Geographical Landscape 118
    • 9.3.7 Pipeline Analysis 118
    • 9.3.8 Competitive Landscape 118
    • 9.3.9 Expert Panel Validation 118
  • 9.4 Contact Us 118
  • 9.5 Disclaimer 118
  • 9.6 Sources 119

List of Tables

  • Table 1: Anti-Hypertensives Market, Global, Revenue ($bn), 2002-2010 12
  • Table 2: Anti-Hypertensives Market, Global, Revenue Forecasts ($bn), 2010-2017 12
  • Table 3: Anti-Hypertensives Market, Global, Annual Cost of Therapy ($), 2002-2010 13
  • Table 4: Anti-Hypertensives Market, Global, Annual Cost of Therapy ($), 2010-2017 13
  • Table 5: Anti-Hypertensives Market, Global, Treatment Usage Patterns (millions), 2002-2010 14
  • Table 6: Anti-Hypertensives Market, Global, Treatment Usage Patterns (millions), 2010-2017 15
  • Table 7: Hypertension Therapeutics Market, Global, Revenue ($bn), 2002-2010 24
  • Table 8: Hypertension Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 24
  • Table 9: Hypertension Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010 26
  • Table 10: Hypertension Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017 26
  • Table 11: Hypertension Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010 27
  • Table 12: Hypertension Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2017 28
  • Table 13: Hypertension Therapeutics Market, Global, Market Segmentation by Geography ($bn), 2002-2010 33
  • Table 14: Hypertension Therapeutics Market, Global, Market Segmentation by Geography ($bn), 2010-2017 34
  • Table 15: PAH Therapeutics Market, Global, Revenue ($m), 2002-2010 38
  • Table 16: PAH Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017 38
  • Table 17: PAH Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010 39
  • Table 18: PAH Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017 39
  • Table 19: PAH Therapeutics Market, Global, Treatment Usage Patterns (thousand), 2002-2010 40
  • Table 20: PAH Therapeutics Market, Global, Treatment Usage Patterns (thousand), 2010-2017 41
  • Table 21: PAH Therapeutics Market, Global, Market Segmentation by Geography ($m), 2002-2010 46
  • Table 22: PAH Therapeutics Market, Global, Market Segmentation by Geography ($m), 2010-2017 47
  • Table 23: Anti-Hypertensives Market, Global, Revenue by Geography ($bn), 2002-2010 49
  • Table 24: Anti-Hypertensives Market, Global, Revenue Forecasts by Geography ($bn), 2010-2017 50
  • Table 25: Anti-Hypertensives Market, The US, Revenue ($bn), 2002-2010 51
  • Table 26: Anti-Hypertensives Market, The US, Revenue Forecasts ($bn), 2010-2017 51
  • Table 27: Anti-Hypertensives Market, The US, Annual Cost of Therapy ($), 2002-2010 52
  • Table 28: Anti-Hypertensives Market, The US, Annual Cost of Therapy ($), 2010-2017 52
  • Table 29: Anti-Hypertensives Market, The US, Treatment Usage Patterns (millions), 2002-2010 53
  • Table 30: Anti-Hypertensives Market, The US, Treatment Usage Patterns (millions), 2010-2017 54
  • Table 31: Anti-Hypertensives Market, Top Five Countries in Europe, Revenue ($bn), 2002-2010 58
  • Table 32: Anti-Hypertensives Market, Top Five Countries in Europe, Revenue Forecasts ($bn), 2010-2017 59
  • Table 33: Anti-Hypertensives Market, Top Five Countries in Europe, Revenue by Country ($bn), 2002-2010 59
  • Table 34: Anti-Hypertensives Market, Top Five Countries in Europe, Revenue Forecasts by Country ($bn), 2010-2017 60
  • Table 35: Anti-Hypertensives Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2010 61
  • Table 36: Anti-Hypertensives Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2010-2017 61
  • Table 37: Anti-Hypertensives Market, Top Five Countries in Europe, Treatment Usage Patterns (millions), 2002-2010 62
  • Table 38: Anti-Hypertensives Market, Top Five Countries in Europe, Treatment Usage Patterns (millions), 2010-2017 63
  • Table 39: Anti-Hypertensives Market, Japan, Revenue ($bn), 2002-2010 67
  • Table 40: Anti-Hypertensives Market, Japan, Revenue Forecasts ($bn), 2010-2017 67
  • Table 41: Anti-Hypertensives Market, Japan, Annual Cost of Therapy ($), 2002-2010 68
  • Table 42: Anti-Hypertensives Market, Japan, Annual Cost of Therapy ($), 2010-2017 68
  • Table 43: Anti-Hypertensives Market, Japan, Treatment Usage Patterns (millions), 2002-2010 69
  • Table 44: Anti-Hypertensives Market, Japan, Treatment Usage Patterns (millions), 2010-2017 70
  • Table 45: Anti-Hypertensives Market, Global, R&D Pipeline by Phase in Hypertension Market, July 2011 77
  • Table 46: Anti-Hypertensives Market, Global, R&D Pipeline by Phase in Pulmonary Arterial Hypertension Market, 2011 81
  • Table 47: Anti-Hypertensives Market, Global, Major M&A Deals, 2005-2011 105
  • Table 48: Anti-Hypertensives Market, Global, Licensing Agreements for Drugs in Phase II and Phase III Stage, 2005-2011 109
  • Table 49: Anti-Hypertensives Market, Global, Licensing Agreements for Approved Drugs, 2005-2011 110

List of Figures

  • Figure 1: Anti-Hypertensives Market, Global, Drivers and Restraints, 2011 11
  • Figure 2: Anti-Hypertensives Market, Global, Revenue Forecasts ($bn), 2002-2017 12
  • Figure 3: Anti-Hypertensives Market, Global, Annual Cost of Therapy ($), 2002-2017 13
  • Figure 4: Anti-Hypertensives Market, Global, Treatment Usage Patterns (millions), 2002-2017 14
  • Figure 5: Anti-Hypertensives Market, Global, Diseased Population (millions), 2002-2017 15
  • Figure 6: Anti-Hypertensives Market, Global, Treatment-Seeking Population (millions), 2002-2017 16
  • Figure 7: Anti-Hypertensives Market, Global, Diagnosed Population (millions), 2002-2017 17
  • Figure 8: Anti-Hypertensives Market, Global, Prescription Population (millions), 2002-2017 18
  • Figure 9: Anti-Hypertensives Market, Global, Branded versus Generic Market Share (%), 2010 21
  • Figure 10: Anti-Hypertensives Market, Treatment Flow Algorithm for Hypertension, 2011 23
  • Figure 11: Hypertension Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 24
  • Figure 12: Hypertension Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017 25
  • Figure 13: Hypertension Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2017 27
  • Figure 14: Hypertension Therapeutics Market, Global, Diseased Population (millions), 2002-2017 28
  • Figure 15: Hypertension Therapeutics Market, Global, Treatment-Seeking Population (millions), 2002-2017 29
  • Figure 16: Hypertension Therapeutics Market, Global, Diagnosis Population (millions), 2002-2017 30
  • Figure 17: Hypertension Therapeutics Market, Global, Prescription Population (millions), 2002-2017 31
  • Figure 18: Hypertension Therapeutics Market, Global, Market Segmentation by Geography (%), 2010 and 2017 32
  • Figure 19: Hypertension Therapeutics Market, Global, Market Segmentation by Geography ($bn), 2002-2017 33
  • Figure 20: PAH Therapeutics Market, Treatment Flow Algorithm for PAH, 2011 37
  • Figure 21: PAH Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 38
  • Figure 22: PAH Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017 39
  • Figure 23: PAH Therapeutics Market, Global, Treatment Usage Patterns (thousand), 2002-2017 40
  • Figure 24: PAH Therapeutics Market, Global, Diseased Population (thousand), 2002-2017 41
  • Figure 25: PAH Therapeutics Market, Global, Treatment-Seeking Population (thousand), 2002-2017 42
  • Figure 26: PAH Therapeutics Market, Global, Diagnosed Population (thousand), 2002-2017 43
  • Figure 27: PAH Therapeutics Market, Global, Prescription Population (thousand), 2002-2017 44
  • Figure 28: PAH Therapeutics Market, Global, Market Segmentation by Geography (%), 2010 and 2017 45
  • Figure 29: PAH Therapeutics Market, Global, Market Segmentation by Geography ($bn), 2002-2017 46
  • Figure 30: Anti-Hypertensives Market, Global, Market Share by Geography (%), 2010 and 2017 48
  • Figure 31: Anti-Hypertensives Market, Global, Revenue Forecasts by Geography ($bn), 2002-2017 49
  • Figure 32: Anti-Hypertensives Market, The US, Revenue Forecasts ($bn), 2002-2017 51
  • Figure 33: Anti-Hypertensives Market, The US, Annual Cost of Therapy ($), 2002-2017 52
  • Figure 34: Anti-Hypertensives Market, The US, Treatment Usage Patterns (millions), 2002-2017 53
  • Figure 35: Anti-Hypertensives Market, The US, Diseased Population (millions), 2002-2017 54
  • Figure 36: Anti-Hypertensives Market, The US, Treatment-Seeking Population (millions), 2002-2017 55
  • Figure 37: Anti-Hypertensives Market, The US, Diagnosed Population (millions), 2002-2017 56
  • Figure 38: Anti-Hypertensives Market, The US, Prescription Population (millions), 2002-2017 57
  • Figure 39: Anti-Hypertensives Market, Top Five Countries in Europe, Revenue Forecasts ($bn), 2002-2017 58
  • Figure 40: Anti-Hypertensives Market, Top Five Countries in Europe, Revenue Forecasts by Country, ($bn), 2002-2017 59
  • Figure 41: Anti-Hypertensives Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2017 61
  • Figure 42: Anti-Hypertensives Market, Top Five Countries in Europe, Treatment Usage Patterns (millions), 2002-2017 62
  • Figure 43: Anti-Hypertensives Market, Top Five Countries in Europe, Diseased Population (millions), 2002-2017 63
  • Figure 44: Anti-Hypertensives Market, Top Five Countries in Europe, Treatment-Seeking Population (millions), 2002-2017 64
  • Figure 45: Anti-Hypertensives Market, Top Five Countries in Europe, Diagnosed Population (millions), 2002-2017 65
  • Figure 46: Anti-Hypertensives Market, Top Five Countries in Europe, Prescription Population (millions), 2002-2017 66
  • Figure 47: Anti-Hypertensives Market, Japan, Revenue Forecasts ($bn), 2002-2017 67
  • Figure 48: Anti-Hypertensives Market, Japan, Annual Cost of Therapy ($), 2002-2017 68
  • Figure 49: Anti-Hypertensives Market, Japan, Treatment Usage Patterns (millions), 2002-2017 69
  • Figure 50: Anti-Hypertensives Market, Japan, Diseased Population (millions), 2002-2017 70
  • Figure 51: Anti-Hypertensives Market, Japan, Treatment-Seeking Population (millions), 2002-2017 71
  • Figure 52: Anti-Hypertensives Market, Japan, Diagnosed Population (millions), 2002-2017 72
  • Figure 53: Anti-Hypertensives Market, Japan, Prescription Population (millions), 2002-2017 73
  • Figure 54: Anti-Hypertensives Market, Global, R&D Pipeline by Indication (%), 2011 74
  • Figure 55: Anti-Hypertensives Market, Global, R&D Pipeline by Phase (%), 2011 75
  • Figure 56: Anti-Hypertensives Market, Global, R&D Pipeline by Phase in Hypertension Market (%), 2011 76
  • Figure 57: Anti-Hypertensives Market, Global, R&D Pipeline by Phase in Pulmonary Arterial Hypertension Market (%), 2011 80
  • Figure 58: Anti-Hypertensives Market, Global, Market Share by Company (%), 2010 90
  • Figure 59: Anti-Hypertensives Market, Global, SWOT - Novartis, 2011 92
  • Figure 60: Anti-Hypertensives Market, Global, SWOT - Merck, 2011 93
  • Figure 61: Anti-Hypertensives Market, Global, SWOT - Daiichi Sankyo, 2011 94
  • Figure 62: Anti-Hypertensives Market, Global, SWOT - Sanofi, 2011 95
  • Figure 63: Anti-Hypertensives Market, Global, SWOT - AstraZeneca, 2011 96
  • Figure 64: Anti-Hypertensives Market, Global, SWOT - United Therapeutics, 2011 98
  • Figure 65: Anti-Hypertensives Market, Global, SWOT - Actelion Ltd, 2011 100
  • Figure 66: Anti-Hypertensives Market, Global, SWOT - Pfizer, 2011 101
  • Figure 67: Anti-Hypertensives Market, Global, Deals by Type (%), 2005-2011 102
  • Figure 68: Anti-Hypertensives Market, Global, M&A Deals by Year, 2005-2011 103
  • Figure 69: Anti-Hypertensives Market, Global, M&A Deals by Geography, 2005-2011 104
  • Figure 70: Anti-Hypertensives Market, Global, Major Licensing Agreements by Indication (%), 2005-2011 107
  • Figure 71: Anti-Hypertensives Market, Global, Major Licensing Agreements by Phase (%), 2005-2011 108
  • Figure 72: Anti-Hypertensives Market, Global, Major Licensing Agreements by Geography (%), 2005-2011 108
  • Figure 73: GBI Research Market Forecasting Model 117
Back to Top